Navigation Links
MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
Date:11/21/2011

DALLAS, Texas, November 21, 2011 /PRNewswire/ --

The report "Leukemia Therapeutics Market (Acute/Chronic Lymphocytic Leukemia & Acute/Chronic Myeloid Leukemia) Pipeline Assessment & Global Market Forecast (2010 - 2020)" analyzes and studies the major market drivers, restraints, and opportunities in North America, & Europe.

Browse market data tables and in-depth TOC on Leukemia Therapeutics Market (Acute/Chronic Lymphocytic Leukemia & Acute/Chronic Myeloid Leukemia) Pipeline Assessment & Global Market Forecast (2010 - 2020).
http://www.marketsandmarkets.com/Market-Reports/chronic-lymphocytic-leukemia-223.html
Early buyers will receive 10% customization on reports.

Leukemia is the cancer of the white blood cells or the bone marrow, which occurs due to an abnormal increase in the count of white blood cells. It is identified by the spread of the diseases (either acute or chronic), and by the type of the blood cell that is affected (lymphocytic or myelocytic). This type of cancer can again be categorized into acute lymphoblastic leukemia (ALL), which accounts for about 12%, chronic lymphocytic leukemia (CLL) which accounts for 35%, acute myelogenous leukemia (AML) which accounts for 29%, and chronic myelogenous leukemia (CML) which accounts for 11% of the total leukemia.

The leukemia therapeutics market [ http://www.marketsandmarkets.com/Market-Reports/chronic-lymphocytic-leukemia-223.html ] was valued at $6.3 billion in 2010 and is expected to reach $11.3 billion by 2020 at a CAGR of 3.84% between 2015 and 2020. The market was dominated by chronic myeloid leukemia in 2010. However, in 2020, the market is expected to be equally dominated by acute lymphocytic leukemia and chronic myeloid leukemia, with sales amounting to $3.91 billion and $3.58 billion respectively.

According to WHO, leukemia is expected to be more prominent in the developed world such as North America and European countries due to genetic factor. The other causes such as environmental factor and radiation exposure are also the causative factors of all the types of leukemia.

The U.S. dominates the leukemia drug market in North America with 62% share; whereas Germany dominates the market of Europe with 31.05% share.

The major players in the market include F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline Pharmaceuticals Limited (U.K.), Novartis International AG (Switzerland), Bristol-Myers Squibb (U.S.), Eisai Co. Ltd (Japan), Biogen Idec (U.S.), ERYtech Pharma (France) Celgene Corporation (U.S.), Genmab A/S (Denmark), Cephalon Inc. (U.S.), Clavis Pharma (Norway), and Pfizer Inc. (U.S.).

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website http://www.marketsandmarkets.com.

Contact:
Mr. Rohan
7557 Rambler Road,
Suite 727, Dallas, TX 75231
Tel: +1-888-6006-441
Email: sales@marketsandmarkets.com
MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com/
http://twitter.com/marketsmarkets


'/>"/>
SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
2. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
3. MarketsandMarkets: Global Biochip (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Market to Reach $5.6 Billion by 2015
4. MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014
5. MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014
6. MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014
7. Marketsandmarkets: Global Minimally Invasive/ Non Invasive Market Worth $24.4 Billion by 2014
8. MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014
9. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014
10. The Leukemia & Lymphoma Society: Accelerating Cures Must Be a Priority
11. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
Breaking Biology News(10 mins):